Pharmaceutical

China’s NMPA approves Henlius’ oesophageal cancer therapy

China has granted approval for Henlius Biotech’s Hansizhuang for patients with oesophageal squamous cell carcinoma (ESCC).

Sep 25, 2023 - 20:00
China’s NMPA approves Henlius’ oesophageal cancer therapy
China has granted approval for Henlius Biotech’s Hansizhuang for patients with oesophageal squamous cell carcinoma (ESCC).
Read the original article

Tags:

Previous Article

Novartis eyes first-line status for its radionucleotide therapy Lutathera

Next Article

Valneva receives JE vaccine supply contract from US DoD

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Minerva hit with FDA rejection for schizophrenia symptom drug

Minerva hit with FDA rejection for schizophrenia sympto...

Feb 28, 2024

UK NHS launches vaccine programme for RSV

UK NHS launches vaccine programme for RSV

Sep 4, 2024

MSD extends peptide collaboration with IRBM

MSD extends peptide collaboration with IRBM

Jun 23, 2023